Androgen receptor polymorphism-dependent variation in prostate-specific antigen concentrations of European men
Bentmar Holgersson, Magdalena × Giwercman, Aleksander EMAS group Bjartell, Anders Wu, Frederick C W Huhtaniemi, Ilpo T O'Neill, Terence W Pendleton, Neil Vanderschueren, Dirk Lean, Michael E J Han, Thang S Finn, Joseph D Kula, Krzysztof Forti, Gianni Casanueva, Felipe F Bartfai, György Punab, Margus EMAS group Lundberg Giwercman, Yvonne #
American Association for Cancer Research
Cancer Epidemiology, Biomarkers & Prevention vol:23 issue:10 pages:2048-56
Androgens acting via the androgen receptor (AR) stimulate production of PSA, which is a clinical marker of prostate cancer. Because genetic variants in the AR may have a significant impact on the risk of being diagnosed with prostate cancer, the aim was to investigate whether AR variants were associated with the risk of having PSA above clinically used cutoff thresholds of 3 or 4 ng/mL in men without prostate cancer.